Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
중증 코로나19 폐렴으로 입원한 환자의 토실리주맙
Clinical Trial
[키워드] 24 hour
95% CI
95% confidence interval
Case report
clinical status
Cohort studies
Coronavirus disease 2019
COVACTA
COVID-19 pneumonia
death
Department
discharge
discharged
dose
elevated
first dose
Hoffmann-La Roche
Hospitalization
Hospitalized
hospitalized patient
Human
hyperinflammation
immune dysregulation
interleukin-6
interleukin-6 receptor
lower mortality
median value
modified intention-to-treat
monoclonal antibody
non-ICU
occurred
outcome
participant
Patient
phase 3 trial
Placebo
Placebo-controlled trials
Primary outcome
randomization
Randomized
randomized trial
randomly assigned patient
receive
retrospective
safety population
second dose
Secondary analyses
Serious Adverse Event
significantly
single intravenous infusion
supplemental oxygen
the patient
the placebo group
Tocilizumab
[DOI] 10.1056/NEJMoa2028700 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2028700 PMC 바로가기 [Article Type] Clinical Trial